Tran Quoc Bao Tran

Tran Quoc Bao Tran

Auto-generated profile, based on publicly available information

Tran Quoc Bao Tran

School of Health and Wellbeing, University of Glasgow , Glasgow

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2022 in EBioMedicine
Verified
Journal Article
Open access
PLPanayiotis Louca
Panayiotis Louca
TTTran Quoc Bao Tran
Tran Quoc Bao Tran
CTClea du Toit
Clea du Toit
PCParaskevi Christofidou
Paraskevi Christofidou
TSTim D. Spector
Tim D. Spector
CMCristina Menni
Cristina Menni
Association studies have identified several biomarkers for blood pressure and hypertension, but a thorough understanding of their mutual dependencies is lacking. By integrating two different high-throughput datasets, biochemical and dietary data, we aim to understand the multifactorial contributors of blood pressure (BP). We included 4,863 participants from TwinsUK with concurrent BP, metabolomics, genomics, biochemical measures, and dietary data. We used 5-fold cross-validation with the machine learning XGBoost algorithm to identify features of importance in context of one another in TwinsUK (80% training, 20% test). The features tested in TwinsUK were then probed using the same algorithm in an independent dataset of 2,807 individuals from the Qatari Biobank (QBB). Our model explained 39·2% [4·5%, MAE:11·32 mmHg (95%CI, +/- 0·65)] of the variance in systolic BP (SBP) in TwinsUK. Of the top 50 features, the most influential non-demographic variables were dihomo-linolenate, cis-4-decenoyl carnitine, lactate, chloride, urate, and creatinine along with dietary intakes of total, trans and saturated fat. We also highlight the incremental value of each included dimension. Furthermore, we replicated our model in the QBB [SBP variance explained = 45·2% (13·39%)] cohort and 30 of the top 50 features overlapped between cohorts. We show that an integrated analysis of omics, biochemical and dietary data improves our understanding of their in-between relationships and expands the range of potential biomarkers for blood pressure. Our results point to potentially key biological pathways to be prioritised for mechanistic studies. Chronic Disease Research Foundation, Medical Research Council, Wellcome Trust, Qatar Foundation.

2 May 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
CTClea du Toit
Clea du Toit
TTTran Quoc Bao Tran
Tran Quoc Bao Tran
NDNeha Deo
Neha Deo
SASachin Aryal
Sachin Aryal
SLStefanie Lip
Stefanie Lip
Sandosh PadmanabhanSandosh Padmanabhan
Sandosh Padmanabhan
Background: Machine learning (ML) is pervasive in all fields of research, from automating tasks to complex decision‐making. However, applications in different specialities are variable and generally limited. Like other conditions, the number of studies employing ML in hypertension research is growing rapidly. In this study, we aimed to survey hypertension research using ML, evaluate the reporting quality, and identify barriers to ML's potential to transform hypertension care. Methods and Results: The Harmonious Understanding of Machine Learning Analytics Network survey questionnaire was applied to 63 hypertension‐related ML research articles published between January 2019 and September 2021. The most common research topics were blood pressure prediction (38%), hypertension (22%), cardiovascular outcomes (6%), blood pressure variability (5%), treatment response (5%), and real‐time blood pressure estimation (5%). The reporting quality of the articles was variable. Only 46% of articles described the study population or derivation cohort. Most articles (81%) reported at least 1 performance measure, but only 40% presented any measures of calibration. Compliance with ethics, patient privacy, and data security regulations were mentioned in 30 (48%) of the articles. Only 14% used geographically or temporally distinct validation data sets. Algorithmic bias was not addressed in any of the articles, with only 6 of them acknowledging risk of bias. Conclusions: Recent ML research on hypertension is limited to exploratory research and has significant shortcomings in reporting quality, model validation, and algorithmic bias. Our analysis identifies areas for improvement that will help pave the way for the realization of the potential of ML in hypertension and facilitate its adoption.

2 May 2026 in European Heart Journal
Verified
Journal Article
Closed access
AIAntonio Iaconelli
Antonio Iaconelli
MMMoustafa I Morsy
Moustafa I Morsy
JFJocelyn M Friday
Jocelyn M Friday
PPPierpaolo Pellicori
Pierpaolo Pellicori
BEBenjamin M P Elyan
Benjamin M P Elyan
JCJohn George Franklin Cleland
John George Franklin Cleland
Background and Aims: Many patients with cancer develop heart failure (HF), and many patients with HF develop cancer. Inter-relationships between their natural histories are rarely reported. Methods: Health records were obtained for a Scottish region. People aged >50 years were classified by the presence or absence of HF, loop diuretics (a pharmacological marker of congestion), and cancer. Incident cancer, mortality, and cause of death were recorded. Results: Of 317 178 people aged >50 years, 11 268 (3.6%) had HF of whom 6276 were prescribed loop diuretics; a further 19 044 (6.0%) received loop diuretics. Thus, 30 312 (9.6%) people met an expanded definition of heart failure (HFexp). Annual cancer incidence was slightly higher for those with HFexp (incidence rate ratio 1.10; P < .001), varying amongst cancer types. For people with neither cancer nor HFexp, mortality was <3% annually; most deaths were cardiovascular. For those with cancer but not HFexp, annual mortality was 6.3% for women and 9.0% for men; most died of cancer. For those with HFexp but not cancer, annual mortality ranged from 6.6% to 18.4% depending on sex and HFexp criteria applied; most deaths were cardiovascular. For those with both cancer and HFexp, annual mortality ranged from 14.5% to 28.4%; cardiovascular and cancer mortality rates were similar. Few patients died at home (∼20%). Conclusions: Patients with HFexp have a slightly higher risk of cancer overall, but this may vary according to cancer type. Patients with both cancer and HFexp have a poor prognosis with a similar proportion of deaths attributed to cancer and cardiovascular disease.

15 February 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ANAna Nogal
Ana Nogal
PLPanayiotis Louca
Panayiotis Louca
TTTran Quoc Bao Tran
Tran Quoc Bao Tran
RBRuth C. Bowyer
Ruth C. Bowyer
PCParaskevi Christofidou
Paraskevi Christofidou
CMCristina Menni
Cristina Menni

1 July 2025 in BMJ Public Health
Verified
Journal Article
Open access
TTTran Quoc Bao Tran
Tran Quoc Bao Tran
SLStefanie Lip
Stefanie Lip
CMChris McParland
Chris McParland
BNBarbara I Nicholl
Barbara I Nicholl
JFJocelyn M Friday
Jocelyn M Friday
Sandosh PadmanabhanSandosh Padmanabhan
Sandosh Padmanabhan
Introduction: Socioeconomic deprivation is a major driver of multimorbidity (multiple long-term conditions, MLTCs) and polypharmacy in ageing populations. However, it is unclear how these inequalities evolve over time or influence early disease progression. Methods: We conducted a population-based longitudinal study of 414 746 adults aged ≥51 years in Greater Glasgow and Clyde, Scotland, using linked administrative health records. Participants were followed at three timepoints (2016, 2019, 2021), with socioeconomic status defined by Scottish Index of Multiple Deprivation (SIMD) deciles. Outcomes included prevalence and progression of MLTCs and medication burden. Zero-inflated negative binomial (ZINB) models estimated the burden of disease and prescribing, and the likelihood of remaining disease-free or prescription-free, adjusted for age and sex. Results: Multimorbidity and prescription burden increased over time across all groups. In 2021, 26.0% of individuals in the most deprived decile (SIMD1) had ≥5 conditions compared with 13.8% in the least deprived (SIMD10). From 2016 to 2021, individuals in SIMD10 were nearly 40% less likely to progress from a single condition to five or more (risk ratio=0.62 (0.60 to 0.63)) compared with SIMD1. ZINB models showed lower expected MLTC counts (incidence rate ratio (IRR)=0.59 (0.58 to 0.60)) and medication burden (IRR=0.91 (0.90 to 0.91)) in SIMD10, but also lower odds of remaining completely disease-free (OR=0.65 (0.63 to 0.68)) or prescription-free (OR=0.44 (0.41 to 0.47)). Findings were consistent in survivor-only sensitivity analyses (n=360 683). Conclusions: Socioeconomic deprivation shapes disease and treatment trajectories from the earliest stages. Individuals in deprived areas experience faster accumulation of conditions and medications. These disparities are not explained by survival differences and highlight the need for equity-focused prevention, tailored care pathways and systems that address the social complexity of multimorbidity.

11 November 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
JOJonathan Olsen
Jonathan Olsen
NNNatalie Anne Harriette Nicholls
Natalie Anne Harriette Nicholls
TTTran Quoc Bao Tran
Tran Quoc Bao Tran
JPJill Pell
Jill Pell
JLJim Lewsey
Jim Lewsey
SPSandosh Padmanabhan
Sandosh Padmanabhan
Objectives: To estimate condition-specific patient travel distances and associated carbon emissions across common chronic diseases in routine National Health Service (NHS) care, and to assess the potential carbon savings of modal shifts in transportation. Design: Retrospective population-based cohort study. Setting: NHS Greater Glasgow and Clyde, Scotland. Participants: 6599 patients aged 50–55 years at diagnosis, including cardiovascular disease (n=1711), epilepsy (n=1044), cancer (n=716), rheumatoid arthritis (RA; n=172) and a matched control group based on age, sex and area-level deprivation (n=2956). Main outcome measures: Annual home-to-clinic distances and associated carbon emissions modelled under four transport modes (petrol car, electric car, bus, train) across five time points: 2-year prediagnosis, diagnosis year and 2-year postdiagnosis. Results: Mean annual travel distances to hospital varied by condition and peaked at diagnosis. Patients with cancer had the highest travel distances (161 km/patient/year for men; 139 km/patient/year for women), followed by RA (approximately 78 km/patient/year). The matched control group travelled <2 km/patient/year on average. Assuming 100% petrol car use, estimated condition-specific emissions ranged from 16.5 kg CO 2 /patient/year to 8.0 kg CO 2 /patient/year. Bus travel resulted in intermediate emissions, estimated between 10.5 and 8.0 kg CO 2 /patient. When travel was modelled using electric vehicles, emissions dropped between 3.5 and 2.7 kg for all conditions. Train travel produced similarly low emissions. Reducing petrol car travel from 100% to 60% lowered emissions up to 6.6 kg CO 2 /patient. Conclusions: Condition-specific estimates of healthcare-related travel emissions provide baseline understanding of the opportunities and challenges for decarbonising healthcare. Emission reduction is most achievable through modal shift, yet such shifts depend on factors beyond NHS control—such as transport infrastructure, digital access and social equity. Multisectoral strategies, including targeted telemedicine and integrated transport and urban planning, are critical to achieving net-zero healthcare while maintaining equitable access to care.